Lipid Regulators Market Forecasts to 2028 - Global Analysis By Product (Monoglycerols, Cholesterol, Sphingomyelin, Diacylglycerols, Glycerophospholipid), Type (Non-Statins, Statins), Phase (Pre-Clinical, Clinical), Application and Geography

According to Stratistics MRC, the Global Lipid Regulators Market is accounted for $7.38 billion in 2022 and is expected to reach $13.58 billion by 2028 growing at a CAGR of 10.7% during the forecast period. Lipids are essential bio molecules for the metabolism to operate as it should. However, an excessive amount of any lipid is thought to be hazardous. In addition to regulating cholesterol, lipids also deal with osteoporosis, which is characterised by weak bones that are easily broken, and they prevent myocardial infarctions, often known as heart attacks. There has been a rise in demand for lipid regulators recently as a result of the frequency of disorders like dyslipidemia. Lipids are typically insoluble in water; however they are readily soluble in alcohols and organic solvents. Lipids are made up of esters and fats with similar properties. Energy storage is one of the fundamental qualities of lipid nutrition, which the human body needs for healthy operation.

According to the 2022 American Heart Association (AHA) report, approximately 244.1 million people were living with ischemic heart disease (IHD) around the world had the highest prevalence rates of IHD in the world in 2020. According to the World Aging Report 2022, the share of the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. By 2050, the number of people aged 65 years or over worldwide is projected to be more than twice the number of children under age 5 and about the same as the number of children under age 12. According to the Centers for Disease Control and Prevention (CDC) data updated in May 2022, from March 2017 to March 2020, 41.9% of Americans were obese.

Market Dynamics:

Driver:

High Prevalence of Lifestyle-related Diseases

Lipids are organic compounds in the form of fats, oils, and hormones that are insoluble in water, and are being extensively used in the pharmaceutical, food, and cosmetics & personal care industries. However, growth in chronic and lifestyle-related diseases is triggering the demand for lipid-based drug delivery systems. Companies in the lipids market are establishing stable revenue streams by expanding output capacities for pharmaceutical lipids. Manufacturers are diversifying the production of functional lipids such as omega-3, phytosterols, and conjugated linoleic acids that help in the management of bone health, blood pressure, and cardiovascular health.

Restraint:

Lack of awareness

The factor that is obstructing the expansion of the lipid regulators market is due to lack of awareness among the people about lipid regulators. In emerging nations, a lack of awareness about innovative treatment methods will impede market expansion. The market will be challenged by a scarcity of qualified workers and a lack of healthcare facilities in developing nations.

Opportunity:

Rise in chronic diseases

The adoption of non-invasive procedures, rising funding levels for the development of cutting-edge and technologically innovative testing products, the prevalence of geriatric and obese populations around the world, rising cardiovascular disease and diabetes cases, and rising geriatric and obese populations are all expected to contribute to the market's growth.

Threat:

Higher risk of medical conditions

For good health, lipids are necessary. However, consuming an excessive amount of them can increase your risk of developing diseases including liver disease and heart disease. Increasing "bad" LDL cholesterol in the blood can increase the risk of heart disease and stroke. This risk can be increased by consuming too much saturated fats in the diet.

COVID-19 Impact

In order to assure a steady supply of lipid products throughout the corona virus crisis, manufacturers in the lipids industry are maintaining optimal inventory levels. To lessen reliance on imports of raw materials, they are expanding their local production capacity. Prior to expanding into new areas, businesses engage in mergers and acquisitions (M&As) to broaden their market reach.

The Branded statins segment is expected to be the largest during the forecast period

The Branded statins segment is estimated to have a lucrative growth, due more successful than other lipid-regulating medications at reducing LDL-cholesterol levels. Atorvastatin, Fluvastatin, Pravastatin, Rosuvastatin, and Simvastatin are a few of the statins that are on the market. Consequently, it is anticipated that as the incidence of dyslipidemia rises, so will the demand for these statins.

The Personal Care & Cosmetics segment is expected to have the highest CAGR during the forecast period

The Personal Care & Cosmetics segment is anticipated to witness the fastest CAGR growth during the forecast period, due to urbanization growth has significantly altered lifestyles across the globe. The personal care and cosmetics business has benefited as a result. Social media and digitization have been extremely important for cosmetics sales. It is anticipated that rising customer preference for cosmetics made with herbal ingredients would contribute to the expansion of the lipids industry. Thus, it is projected that an increase in cosmetics sales will stimulate the lipids industry.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to increased demand for nutraceutical products, expansion in the pharmaceutical industry, rising per capita disposable income in the nation, and significant demand for lipids in the personal care & cosmetics, food & beverage, and nutraceutical industries, the country has seen an increase in lipid demand.

Region with highest CAGR:

North American is projected to have the highest CAGR over the forecast period, owing to the highest prevalence of Obesity and Diabetes in the world. The type 2 diabetes, the most common form of the disease, is more likely to develop in those who are overweight or obese. Dyslipidemia is predicted to become more common as diabetes prevalence raises the risk of dyslipidemia. The health care systems in rising nations are advanced and well-organized, nonetheless. Additionally, these systems support innovation and research. These nations benefit from the presence of several international market players as a result.

Key players in the market

Some of the key players profiled in the Lipid Regulators Market include Abbott Laboratories, Novartis Merck Millipore Limited, Sun Pharmaceutical Industries Limited, Astellas Pharma, Moderna Inc., Bentley Pharmaceuticals, Archer Daniels Midland Company, AstraZeneca, Andrx Corporation, Bristol-Myers Squibb, NOF Corporation, Stepan Company, Abitec Corporation, Amgen, Teva Pharmaceuticals, Matreya Llc, Lipoid GmbH., Avanti Polar Lipids Inc. and Tokyo Chemical Industry Co., Ltd.

Key Developments:

In May 2022, Sun Pharmaceutical Industries Limited launched a first-in-class oral drug, Bempedoic Acid, in India for reducing low-density lipoprotein (LDL) cholesterol. The company launched the drug under the brand name Brillo.

In December 2021, Novartis announced that its Leqvio (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C), with two doses a year, following an initial dose and one every three months, has been approved by the US Food and Drug Administration (FDA).

In May 2020, Moderna Inc., a U.S.-based pharmaceutical company, extended a deal with Corden Pharma to secure large volume of lipids used to produce its experimental COVID-19 vaccine in order to meet the increasing demand for the vaccine

Products Covered:

• Monoglycerols
• Cholesterol
• Sphingomyelin
• Diacylglycerols
• Glycerophospholipid
• Fatty Acids
• Triglycerides
• Phospholipids
• Sphingolipids
• Ionizable Lipids
• Other Products

Types Covered:

• Non-Statins
• Statins
• Other Types

Phases Covered:

• Pre-Clinical
• Clinical

Applications Covered:

• Pharmaceuticals
• Retail
• Online
• Personal Care & Cosmetics
• Food & Beverages
• Nutrition & Supplements
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances